Ipilimumab in patients with melanoma and autoimmune disease
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207313/ |